

Prospective longitudinal voxel-based morphometry study of major depressive disorder in young individuals at high familial risk

T. Nickson¹, S. W. Y. Chan², M. Pappmeyer^{1,3}, L. Romaniuk¹, A. Macdonald¹, T. Stewart¹, S. Kielty¹, S. M. Lawrie¹, J. Hall^{1,4}, J. E. Sussmann¹, A. M. McIntosh^{1,5} and H. C. Whalley^{1*}

¹Division of Psychiatry, University of Edinburgh, Edinburgh, UK

²Clinical Psychology, University of Edinburgh, Edinburgh, UK

³Translational Research Center, University Hospital of Psychiatry, University of Bern, Bern, Switzerland

⁴Neuroscience and Mental Health Research Institute, Cardiff University, Cardiff, UK

⁵Centre for Cognitive Ageing and Cognitive Epidemiology, University of Edinburgh, Edinburgh, UK

Background. Previous neuroimaging studies indicate abnormalities in cortico-limbic circuitry in mood disorder. Here we employ prospective longitudinal voxel-based morphometry to examine the trajectory of these abnormalities during early stages of illness development.

Method. Unaffected individuals (16–25 years) at high and low familial risk of mood disorder underwent structural brain imaging on two occasions 2 years apart. Further clinical assessment was conducted 2 years after the second scan (time 3). Clinical outcome data at time 3 was used to categorize individuals: (i) healthy controls ('low risk', $n = 48$); (ii) high-risk individuals who remained well (HR well, $n = 53$); and (iii) high-risk individuals who developed a major depressive disorder (HR MDD, $n = 30$). Groups were compared using longitudinal voxel-based morphometry. We also examined whether progress to illness was associated with changes in other potential risk markers (personality traits, symptoms scores and baseline measures of childhood trauma), and whether any changes in brain structure could be indexed using these measures.

Results. Significant decreases in right amygdala grey matter were found in HR MDD *v.* controls ($p = 0.001$) and *v.* HR well ($p = 0.005$). This structural change was not related to measures of childhood trauma, symptom severity or measures of sub-diagnostic anxiety, neuroticism or extraversion, although cross-sectionally these measures significantly differentiated the groups at baseline.

Conclusions. These longitudinal findings implicate structural amygdala changes in the neurobiology of mood disorder. They also provide a potential biomarker for risk stratification capturing additional information beyond clinically ascertained measures.

Received 5 August 2015; Revised 13 February 2016; Accepted 20 February 2016; First published online 10 June 2016

Key words: Amygdala, bipolar disorder, hippocampus, major depressive disorder, voxel-based morphometry.

Introduction

Bipolar disorder (BD) and major depressive disorder (MDD) are highly heritable mood disorders that share a complex overlapping genetic architecture (McGuffin *et al.* 2003; Liu *et al.* 2011; Schulze *et al.* 2014). Close relatives of BD patients are also at greater risk of developing other major psychiatric conditions, in particular MDD (Shih *et al.* 2004). A substantial proportion of the heritability for mood disorders is explained by a polygenic component where many

alleles of individually small effect sizes confer risk to BD and MDD in aggregate. Other factors, however, also contribute to risk, including stressful life events in childhood and personality traits such as higher neuroticism and lower extraversion (Kendler *et al.* 2006).

Both BD and MDD are disorders of emotion regulation and are characterized by episodic elevation and/or depression of mood. Difficulties with mood regulation in these disorders are likely to derive from disturbances in neural systems mediating emotion processing. Neuroimaging studies in patient groups indicate abnormalities in components of the cortico-limbic network, with particular emphasis on altered structure and function of the amygdala, hippocampus and cingulate cortex (Phillips *et al.* 2003; Hajek *et al.* 2009;

* Address for correspondence: Heather Whalley, Ph.D., Division of Psychiatry, University of Edinburgh, Royal Edinburgh Hospital, Morningside Park, Edinburgh EH10 5HF, UK.
(Email: heather.whalley@ed.ac.uk)

Savitz & Drevets, 2009; Bora *et al.* 2012; Sacher *et al.* 2012). Models propose either a loss or reduction of higher-order cognitive control by prefrontal regions over the amygdala, or conversely a hyperactive limbic network overriding this cortical control (Phillips *et al.* 2003).

The majority of neuroimaging studies in mood disorder have, however, been conducted on patients with longstanding illness. A number of studies have, however, begun to examine structural neuroimaging features in familial high-risk populations, both in BD and MDD (Hajek *et al.* 2009; Baare *et al.* 2010; Chen *et al.* 2010; Amico *et al.* 2011; Karchemskiy *et al.* 2011; Bechdolf *et al.* 2012; Alemany *et al.* 2013; Kelley *et al.* 2013; Eker *et al.* 2014; Romanczuk-Seiferth *et al.* 2014). However, a consensus of findings has yet to emerge, with some studies reporting increases in volume of cortico-limbic structures, some reporting decreases or no change. Some inconsistency may relate to the cross-sectional nature of the studies and issues relating to the timing of sampling in relation to overall risk trajectories, along with other methodological differences.

There is also a relative paucity of studies examining neuroprogressive change, its relationship with changing features of illness, and in particular during early phases of illness development. It is unclear therefore whether structural abnormalities reported in patient groups are confounded by secondary effects of long-term illness or medication. Similarly, the timing of the onset of these abnormalities and how trait-related features and neurobiology change over the early course of illness development remain uncertain. These are critical issues from a clinical perspective for informing predictive models of risk, and are the focus of the current study.

The Scottish Bipolar Family Study (BFS) is a prospective longitudinal imaging study examining young individuals (16–25 years) at high familial risk of mood disorder, along with a group of healthy controls with no family history, with the aim of addressing the above issues (Whalley *et al.* 2011). In previous imaging studies on this sample at baseline, when all individuals were unaffected, we reported abnormal amygdala function during an executive processing task in the high-risk group *v.* controls (Whalley *et al.* 2011), along with abnormal cortico-limbic white matter connections (Sprooten *et al.* 2011). Activation of the amygdala was also found to be related to cumulative genetic risk for BD using polygenic risk profiling (Whalley *et al.* 2012). Other studies have also reported findings of altered cortico-limbic structure or function in unaffected relatives of mood disorder patients (Levesque *et al.* 2011; Mannie *et al.* 2014; Miskowiak *et al.* 2015). In terms of neurodevelopmental trajectory, therefore, these findings begin to suggest that

cortico-limbic abnormalities are not restricted to established illness, nor are they related to confounding effects of medication, and indeed may be related to the overall burden of genetic risk variants. Whether these abnormalities can distinguish those at greatest risk for illness, how they change over the course of illness development, or how they relate to other non-genetic risk factors for illness, have yet to be fully determined.

Over the course of the BFS a number of individuals have developed a mood disorder, predominantly MDD [defined as meeting formal diagnostic criteria, Diagnostic and Statistical Manual of Mental Disorders, 4th edition (DSM-IV)]. How these limbic abnormalities develop over early phases of illness has, however, yet to be fully addressed (Whalley *et al.* 2013; Pappmeyer *et al.* 2015). The current study therefore reports longitudinal structural imaging findings using the most up-to-date clinical information on the BFS participants (from time 3; T3). We utilized voxel-based morphometry approaches to examine prospective longitudinal structural changes over time to inform markers of risk of mood disorder (MDD). Based on previous findings (Hajek *et al.* 2009; Bora *et al.* 2012; Sacher *et al.* 2012), we hypothesized that there would be grey matter loss in the amygdala, hippocampus, anterior cingulate cortex and prefrontal grey matter in those at high familial risk who develop illness *v.* those who are at high familial risk but have remained well, and *v.* healthy controls. Along with longitudinal structural imaging changes we also sought to test whether progress to illness was associated with changes in other potential risk markers, namely personality traits of high neuroticism and low extraversion, changes in symptoms scores and baseline measures of childhood trauma (Heim & Nemeroff, 2001; Peyrot *et al.* 2014). We also examine whether any changes in brain structure could potentially be indexed using these clinically ascertained measures.

Method

Initial baseline recruitment

Baseline recruitment has been described in full previously (Sprooten *et al.* 2011; Whalley *et al.* 2011; Pappmeyer *et al.* 2015). Briefly, at the beginning of the study (time 1, T1), individuals with a diagnosis of bipolar I disorder were identified by psychiatrists across Scotland. Diagnosis was confirmed with the OPCRIT symptom checklist (McGuffin *et al.* 1991) using data from clinical notes and the Structured Clinical Interview for DSM-IV (SCID; First *et al.* 2002). Each affected subject was asked to identify members of close family aged 16–25 years. Following informed

consent, unaffected individuals with at least one first-degree or two second-degree relatives with bipolar I disorder were invited to participate. For the majority of cases (about 90%) the high-risk individuals were first-degree relatives of the ill family member. Only three of the HR well individuals and one HR MDD had (two or more) second-degree relatives with BD. Unaffected, unrelated comparison subjects with no personal or family history of BD were identified from the social groups of the high-risk subjects and matched for age, gender and intelligence quotient (IQ) to the high-risk group. Comparison subjects were also screened using the SCID (First *et al.* 2002). Exclusion criteria for both groups at initial recruitment included a personal history of major depression, mania or hypomania, psychosis, or any major neurological or psychiatric disorder, a history of substance dependence, learning disability, or any history of head injury that included loss of consciousness and any contraindications to magnetic resonance imaging (MRI). No group differences in lifetime substance misuse were observed previously in this sample (Whalley *et al.* 2011). Written informed consent was obtained. The study was approved by the Multi-Centre Research Ethics Committee for Scotland.

Current study population

Participants were recruited for the current study as part of the BFS as described above. Participants, including controls, have been followed up on three occasions 2 years apart (Whalley *et al.* 2015). Only the first two occasions [T1, time 2 (T2)] contained imaging assessments, the third assessment (T3) being primarily a follow-up clinical assessment. All participants, controls and high risk, were interviewed by one of two experienced psychiatrists (A.M.M., J.E.S.) using the SCID (First *et al.* 2002) to confirm the lifetime absence of any Axis I disorders at T1, and at T2 to determine the presence of any mood disorder meeting diagnostic criteria over the intervening period. At T3 diagnostic status was determined either by face-to-face assessment, or through accessing clinical records at the National Health Service (NHS) as to whether a clinical diagnosis had been made or not (Whalley *et al.* 2015). For a number of individuals ($n=9$), it was not possible to determine the clinical status at T3, either the general practitioner (GP) did not provide details or the GP address was unknown. In the absence of further clinical information indicating that they had become unwell, and since they had remained well over the previous two assessments, these individuals were presumed to have remained well. This, however, necessitated an additional confirmatory analysis excluding these individuals, reported below. If other disorders were

present along with depressive features (e.g. borderline personality disorder, $n=1$; alcoholism, $n=1$; or episodes of psychosis, $n=1$) these individuals were excluded from the current analysis.

Manic and depressive symptoms were rated using the Young Mania Rating Scale (YMRS; Young *et al.* 1978) and the Hamilton Rating Scale for Depression (HAM-D; Hamilton, 1960), and the presence of psychotic symptoms was assessed using the Positive and Negative Syndrome Scale (PANSS, Kay *et al.* 1987). Estimates of trait-liability to mood disorder (neuroticism and extraversion) were measured using the NEO Five Factor Inventory (NEO-FFI; McCrae & John, 1992). Childhood trauma was measured using the 18-item Childhood Trauma Questionnaire (CTQ; Bernstein & Fink, 1988).

The current study concerns structural brain changes between T1 and T2 in relation to the development of MDD at any time throughout the study. The final sample consisted of 131 individuals categorized into three groups: (i) healthy controls who remained well ($n=48$; note that seven control individuals developed MDD; however, due to small group size these individuals were not included in the current analysis); (ii) familial high-risk participants who remained well throughout the study (HR well, $n=53$); and (iii) familial high-risk participants who developed a mood disorder (MDD) at any time throughout the period of study (21 by T2, a further nine by T3; HR MDD, $n=30$; also of note is that two HR individuals had developed BD over the course of the study, similar to above these individuals were not included in the current analyses).

The mean interval between T1 and T2 was 2.12 (s.d. = 0.13), 2.24 (s.d. = 0.15) and 2.24 (s.d. = 0.19) years for the control, HR well and HR MDD groups, respectively. The mean interval between T2 and T3 was 2.73 (s.d. = 0.13), 2.67 (s.d. = 0.14) and 2.66 (s.d. = 0.18) years for the control, HR well and HR MDD groups, respectively. Five individuals from the HR MDD group were on antidepressant medication at T2. An additional subsequent confirmatory analysis was therefore performed excluding these individuals to explore the confounding effects of medication.

Image processing and analysis

All participants were scanned at the Edinburgh University Brain Research Imaging Centre (BRIC) on a GE 1.5T Signa scanner (GE Medical). The T1 sequence was a coronal gradient echo sequence with the magnetization preparation (MPRAGE) yielded 180 contiguous 1.2-mm coronal slices (matrix = 192×192 ; field of view = 24 cm; flip angle 8°).

After reconstruction from raw dicom format to nifti via dcm2nii, structural data were analysed with

FSL-voxel-based morphometry (FSL-VBM) (Douaud *et al.* 2007) (<http://fsl.fmrib.ox.ac.uk/fsl/fslwiki/FSLVBM>), an optimized VBM protocol (Good *et al.* 2001; Smith *et al.* 2004) carried out within the FSL environment (Smith *et al.* 2004). Briefly, all structural images, one for each participant and time point, were brain-extracted and grey matter-segmented before being registered to the MNI 152 standard space using non-linear registration. The resulting images were then averaged and flipped along the *x*-axis to create a left-right symmetric, study-specific grey matter template. Next, all native grey matter images were non-linearly registered to this study-specific template and 'modulated' to correct for local expansion (or contraction) due to the non-linear component of the spatial transformation. The modulated grey matter images were then smoothed with an isotropic Gaussian kernel with a sigma of 3 mm. The choice of smoothing kernel was selected in order to maximize the ability to detect differences in the medial temporal lobe regions as described in our prior hypotheses. The smoothed, normalized grey matter images were compared longitudinally between the three groups: controls, HR well and HR MDD. This was done using a voxel-wise general linear model (GLM) with a repeated-measures design including all three groups over both time points. The model was applied using permutation-based non-parametric testing in the FSL package *randomise*. The analysis plan was to examine differences in longitudinal change over time between the three groups (controls, HR well and HR MDD).

Results in grey matter were considered significant for $p < 0.05$, after correction for multiple comparisons using the threshold-free cluster enhancement (TFCE) approach (Smith & Nichols, 2009) in the FSL *randomize* package which avoids using an arbitrary threshold for the initial cluster formation. Based on our *a priori* hypothesis, small volume corrections were applied for the bilateral amygdala, hippocampus and anterior cingulate cortex created using the Harvard-Oxford sub-cortical structural atlas (Desikan *et al.* 2006). Prefrontal abnormalities were examined at the whole-brain level. All coordinates are quoted in Montreal Neurological Institute (MNI) convention (<http://www.mni.mcgill.ca>) and images are overlaid onto a standard brain in MNI space using FSLView software package. Demographic and clinical data were analysed using one-way analyses of variance, χ^2 tests or Kruskal-Wallis tests where appropriate using SPSS (USA).

Relationship between grey matter change and individual risk markers

We subsequently examined the association between imaging changes over time and measures of childhood

trauma, trait-liability and mood state. Imaging data were extracted using the significant clusters of difference (mean of the cluster) between groups and subsequently related to total CTQ scores at baseline, measures of depressive symptoms (from HAM-D scores), and measures of trait-liability (neuroticism and extraversion) using both baseline and change in scores over time. This was performed in SPSS using correlation analysis on the whole sample whilst controlling for group status.

Results

Demographic data

Demographics, clinical details and behavioural measures are presented in Table 1. Groups did not differ with respect to age, gender or IQ as measured by the National Adult Reading Test (NART; Nelson, 1982).

For the HR-MDD individuals ($n = 30$), at T2, nine individuals from this group were well (becoming ill later) and 21 individuals were diagnosed as MDD (all assessed using the SCID). Of the latter, 12 individuals were classed as single episode and nine were classed as recurrent. Three individuals scored >15 on the HAM-D. The highest score for the YMRS was a score of 5 in one individual; the remaining individuals scored 0–2. For the PANSS positive scores, two individuals scored 9; the remainder scored 7–8 (7 being equivalent to null).

At T3, 10 individuals were classed as well, one individual was deceased and the remainder were classed as MDD. Of the latter group, seven diagnoses were determined through GP contact and for whom we could not determine further detailed subtype diagnoses. Of those 14 who were MDD assessed using the SCID, two were single episode and 12 were classed as recurrent. Three individuals scored >15 on the HAM-D. The highest score on the YMRS was a score of 4 in one individual; the remaining subjects scored 0–2. For the PANSS positive, one individual scored 14, one scored 12, and the remainder scored 7–8.

Between-group differences in brain structure

Comparisons of groups at the whole-brain level did not reveal any significant longitudinal grey matter changes over time between the groups in the prefrontal cortex or in any other region. Region of interest analysis in the anterior cingulate cortex also did not reveal any significant group differences. However, significant differences were reported in the right amygdala using the *a priori* region of interest approach [cluster extent = 488 mm³, peak MNI coordinates = (57, 56, 27), $p_{\text{corr}} < 0.017$; see Fig. 1]. This cluster also overlapped with the hippocampal region of interest; however,

Table 1. Demographics, and clinical, behavioural and temperament measures

	Controls (<i>n</i> = 48)	High-risk well (<i>n</i> = 53)	High-risk MDD (<i>n</i> = 30)	Significance	
	Mean/median (s.d./IQR)	Mean/median (s.d./IQR)	Mean/median (s.d./IQR)	<i>F</i> / χ^2	<i>p</i>
Demographics					
Mean age, years	20.50 (2.46)	21.24 (2.84)	20.70 (3.02)	0.90	0.41
Gender, male:female	19:29	29:24	12:18	1.42	0.24
Mean NART IQ	109.65 (7.17)	109.87 (8.20)	106.73 (9.38)	1.57	0.21
Clinical, personality, and childhood trauma measures					
HAM-D (T1) ^a	0.60 (1.08)	1.0 (2.10)	3.43 (4.47)	14.30	<0.01 ^{c,d}
HAM-D (T2) ^a	1.37 (2.03)	1.49 (3.00)	5.48 (5.85)	15.32	<0.01 ^{c,d}
HAM-D (T3) ^{a,b}	0.95 (1.21)	1.9 (2.65)	5.29 (7.89)	8.61	0.01 ^{c,d}
YMRS (T1) ^a	0.11 (0.00)	0.14 (0.00)	0.43 (0.25)	5.62	0.06
YMRS (T2) ^a	0.24 (0.00)	0.61 (0.00)	0.48 (0.00)	2.61	0.27
YMRS (T3) ^{a,b}	0.15 (0.00)	0.58 (0.00)	0.65 (1.00)	3.59	0.17
Anx (T1)	0.50 (2.00)	0.00 (1.00)	1.00 (2.25)	8.18	0.017 ^{c,d}
Anx (T2)	0.00 (1.00)	0.00 (1.50)	1.00 (1.75)	11.00	0.004 ^{c,d}
Neuroticism (T1) ^a	19.00 (14.00)	19.00 (12.00)	31.00 (18.25)	16.32	<0.001 ^{c,d}
Neuroticism (T2) ^a	18.50 (10.25)	18.00 (8.75)	31.00 (11.00)	24.70	<0.001 ^{c,d}
Extraversion (T1) ^a	32.00 (7.00)	30.00 (5.00)	27.00 (10.25)	11.84	0.003 ^{c,d}
Extraversion (T2) ^a	32.00 (5.25)	29.00 (8.25)	27.00 (8.00)	15.46	<0.001 ^{c,d}
CTQ (T1) ^a	1.00 (2.00)	1.00 (3.00)	2.00 (6.25)	11.11	0.004 ^{c,d}

MDD, Major depressive disorder; s.d., standard deviation; IQR, interquartile range; NART, National Adult Reading Test; IQ, intelligence quotient; HAM-D, Hamilton Rating Scale for Depression; T1, time 1; T2, time 2; T3, time 3; YMRS, Young Mania Rating Scale; Anx, anxiety; CTQ, Childhood Trauma Questionnaire.

^a Kruskal–Wallis tests, median and IQR presented for skewed variables.

^b From those individuals who attended face-to-face assessment.

^{c,d} Pair-wise comparisons indicated significant group differences between controls and high-risk MDD and between high-risk well and high-risk MDD; see text.

since the bulk of this cluster and the peak was centered in the amygdala we refer to the result as such.

Formal pair-wise comparison of the extracted amygdala data (mean of the cluster) indicated significant group \times time interactions between the controls and HR MDD ($p=0.001$, $F=12.954$), between the HR well and HR MDD ($p=0.005$, $F=8.197$), but not between the controls and HR well groups. Graphs of extracted amygdala grey matter for the cluster of difference revealed that there was a small increase in both the control and HR well groups between T1 and T2; by contrast, the HR MDD group demonstrated a reduction in grey matter over the two time points (Fig. 2).

Removing the five individuals who were on medication at T2 did not alter the findings of grey matter differences in the amygdala over time between groups ($p=0.003$, $F=6.18$), nor did excluding the nine participants in the HR well group who were presumed well due to unavailable follow-up clinical data at T3 ($p=0.002$, $F=6.66$). Similarly, removing the individuals who became ill at T3 did not alter the findings ($p=0.002$, $F=6.45$).

Examining findings cross-sectionally at T1 and T2 separately indicated no significant differences at the whole-brain level between the groups, nor for the anterior cingulate region of interest. There were, however, significant group differences for the amygdala at T1 but not at T2 based on extracted data (T1: $F=3.363$, $p=0.038$; T2: $F=0.709$, $p=0.494$). Pair-wise t test comparisons indicated significant differences between controls and HR MDD at T1 only (controls *v.* HR MDD T1: $F=2.542$, $p=0.013$; T2: $F=0.101$, $p=0.274$; HR well *v.* HR MDD T1: $F=1.810$, $p=0.074$; T2: $F=1.055$, $p=0.294$; controls *v.* HR well, T1: $F=1.024$, $p=0.310$, T2: $F=0.172$, $p=0.864$).

Between-group differences in longitudinal symptom severity and trait-liability measures

There were no significant differences between the groups in terms of longitudinal change in symptom severity scores or personality measures between T1 and T2 (HAM-D $\chi^2=2.971$, $p=0.226$; neuroticism $\chi^2=0.476$, $p=0.788$; extraversion $\chi^2=2.879$, $p=0.237$).




Fig. 1. Longitudinal structural change within the amygdala as assessed by voxel-based morphometry. Decreases over time in high-risk individuals who develop major depressive disorder over the course of the study *v.* those that remain well, and healthy controls over a 2-year inter-scan period: (a) coronal section; (b) sagittal section.

As expected, however, there were significant differences between groups for cross-sectional measures of depression indexed by the HAM-D, with the HR MDD group scoring highest across all time points (T1, $p < 0.01$; T2, $p < 0.01$; and T3, $p = 0.01$). Further, pair-wise t tests show that significant differences existed between controls and HR MDD (T1, $p < 0.001$; T2, $p < 0.001$ and T3, $p = 0.02$) and between HR well and HR MDD (T1, $p = 0.001$; T2, $p < 0.001$; and T3, $p = 0.04$). There were no significant differences between groups in terms of mania scores determined from the YMRS for any assessment points. The HR MDD group also demonstrated significantly increased levels of sub-diagnostic anxiety as measured by the Temperament Evaluation of the Memphis, Pisa, Paris, and San Diego Autoquestionnaire (TEMPS-A) at each

time point, and these were significantly higher than controls and HR well individuals; see [Table 1](#).

There were also significant differences between the three groups for baseline measures of neuroticism ($p < 0.001$), extraversion ($p = 0.003$) and childhood trauma (CTQ total, $p = 0.004$); see [Table 1](#). Specifically, the HR MDD group showed the highest level of neuroticism and CTQ, and lowest levels of extraversion. For neuroticism, extraversion and CTQ, pair-wise comparisons indicated significant differences between the controls and HR MDD groups ($p < 0.001$, $Z = 3.563$; $p = 0.001$, $Z = 3.293$; $p = 0.001$, $Z = 3.340$, respectively), between the HR well and HR MDD groups ($p < 0.001$, $Z = 3.714$; $p = 0.016$, $Z = 2.407$; $p = 0.039$, $Z = 2.861$, respectively), but not between the controls and HR well individuals.

Relationship between imaging findings and symptom severity and trait-liability measures

We examined the relationship between the VBM measures of amygdala grey matter change over time and measures of depression from the HAM-D (baseline, T2, and change in score between T1 and T2), anxiety (from the TEMPS-A baseline, T2 and change in score between T1 and T2) neuroticism, extraversion (baseline, T2 and change in score between T1 and T2), and CTQ (baseline only). There were no significant associations in the whole sample controlling for group status, nor within groups separately.

Discussion

In the current study we demonstrated longitudinal structural decreases over time in the amygdala in a group of individuals who were at high familial risk of developing a mood disorder and who became ill over the course of the study, *v.* high-risk individuals who remained well, and healthy controls with no family history of mood disorder. The findings indicate that dynamic structural changes in the amygdala are associated with the development of MDD in this young sample. Measures of symptom severity, sub-diagnostic anxiety, neuroticism and extraversion, and CTQ significantly differentiated the groups at baseline prior to illness, and therefore may therefore constitute vulnerability markers of illness. However, changes in these non-imaging risk factors between assessments did not associate with illness development, nor did they relate significantly to the imaging findings. Taken together therefore these findings indicate that imaging measures may more closely follow the dynamic route to illness than clinically ascertained measures of risk.

Converging lines of evidence suggest that the amygdala plays an important role, along with wider




Fig. 2. Group \times time interaction. Graphical view of raw data extracted from a cluster of longitudinal change over time between groups. HR Well, High-risk well; HR MDD, high-risk major depressive disorder. Values are means, with standard deviations represented by vertical bars.

prefrontal and limbic networks, in responding to emotional salience of stimuli. The amygdala is therefore a key structure in the formation and stability of affective states (LeDoux, 2000). Previous imaging studies of the amygdala in MDD have most consistently demonstrated abnormally increased functional activation in response to negative or non-emotional stimuli in patient groups, also seen in unaffected relatives (Drevets, 2003; Drevets *et al.* 2008; Whalley *et al.* 2011; Swartz *et al.* 2014), along with impaired prefrontal–amygdala connectivity (Matthews *et al.* 2008; Almeida *et al.* 2009). Such circuits are therefore considered key to the emotion-regulation difficulties experienced in the disorder (Phillips *et al.* 2003). Structural studies comparing cases and controls have, however, been generally less directionally consistent, or indeed report no differences (Frodl *et al.* 2008; Arnone *et al.* 2012). There is growing evidence of increased volumes of the amygdala early on in the disease course, for example in first-episode (Frodl *et al.* 2002, 2003), and in high-risk cohorts (Boccardi *et al.* 2010; Rao *et al.* 2010; Saleh *et al.* 2012; Romanczuk-Seiferth *et al.* 2014), indicating potential differences in the trajectory of developmental processes. Although we did not report significant cross-sectional baseline differences in the amygdala in the current study, we do report dynamic structural changes within the right amygdala around the period of illness development which manifested as a decrease over time in those who developed MDD. In those who remained well, and in the healthy control group, there was an increase in grey matter over time in the amygdala which we therefore interpret as reflecting normal

neurodevelopment in this region in this relatively young cohort of individuals who are still reaching levels of neurobiological maturity. This is notably highly consistent with a previous study reporting that adolescents during early phases of the mood disorder do not exhibit normal increases in amygdala volume that occur during healthy adolescent neurodevelopment (Bitter *et al.* 2011).

This finding was only significant for the right amygdala. Previous studies examining amygdala structure in depression have provided equivocal results regarding hemispheric lateralization (Hamilton *et al.* 2008). Further, given the paucity of other longitudinal studies, we believe that currently any conclusions about laterality should be undertaken with caution. Regardless, the current study adds to a currently rather limited literature of longitudinal change in brain structure associated with the onset of mood disorder in young participants at increased risk (Whittle *et al.* 2015). The findings begin to indicate timelines for abnormal neurodevelopment during the early course of illness. Whether such structural changes are a cause or consequence of active disease processes, however, remains unclear. Also, whether such changes are able to inform important clinical distinctions can only be determined with further follow-up of the cohort. For example, whether it is possible to distinguish those who have a single episode of unipolar depression *v.* those who manifest a more severe recurrent course, or indeed who go on to develop BD or other mental health problems. Finally, how such abnormalities relate to wider prefrontal circuitry abnormalities reported in patients has also yet to be established.

One other main factor that has previously been associated with the risk of developing mood disorder is anxiety disorder, which has a particularly strong relevance in the current context given its reported association with the amygdala. We would like to stress, however, that at recruitment any individuals who met diagnostic criteria for an anxiety disorder were not included in the study. Further, we report no association either between the change in anxiety scores from the TEMPS-A and changes in the amygdala grey matter, or any significant associations cross-sectionally. We cautiously conclude therefore that these findings represent change associated with the development of MDD rather than to concurrent anxiety features

We also acknowledge several limitations of the current study. The longitudinal nature of such a study spanning 6+ years and the necessity for utilizing a consistent imaging strategy has meant that imaging protocols can begin to look dated in terms of slice thickness and field strength. However, we believe this is inherent to any long-term, longitudinal study and does not affect the valuable contribution of the data.

Also, although the presence of a family history of mental illness is one of the highest risk factors for depression, other factors also contribute to the overall pattern of risk. Among these are early stressful life events, and the personality traits of neuroticism (high) and extraversion (low) which are thought to relate to maladaptive cognitive and emotional processing (Heim & Nemeroff, 2001; MacMillan *et al.* 2001; Kendler *et al.* 2006; Chan *et al.* 2007; Hovens *et al.* 2010). Notably, these measures at baseline differentiated those at high risk who became ill *v.* those who remained well over the course of 4 years, indicating the importance of these measures in informing wider models of risk prediction. Although we consider it an important finding that individuals who go on to develop MDD at follow-up have significantly increased levels of symptoms as measured by the HAM-D and increased neuroticism since they may indicate important predictors of subsequent illness, we also note that this could equally reflect the prodromal phase of a mood disorder. We stress, however, that no individuals met diagnostic criteria for a mood disorder at study entry. In the current study, however, none of these measures was directly related to the structural imaging findings, nor were changes in these scores associated with the developmental trajectory of illness onset. We interpret these findings therefore as suggesting that imaging measures are more sensitive to changes associated with the dynamic route to illness than these clinically ascertained measures of risk. We also note as an additional limitation that the lack of relationship between change in clinical and trait features

of the disorder with imaging features could be attributable to lack of power (limited range of change in the scores), or to the fact that these measures were not specifically designed to measure change *per se*. In particular, personality features are considered to be stable traits across the lifespan. The lack of associations between these measures should therefore be viewed cautiously.

A particular strength of the current study was the use of a young, relatively large, well-characterized cohort followed up over 4+ years on whom we are continuing to collect data. By the very nature of the cohort the clinical picture is one of dynamic change. It is possible, if not likely, that for some individuals for whom an early diagnosis of MDD may ultimately herald a diagnosis of BD, as was the case for two individuals in the study (Hillegers *et al.* 2005). These findings should therefore be considered in this context. We also note that conversion rates (for MDD) are similar to those reported in other prospective longitudinal studies examining the clinical course of young relatives of bipolar individuals (Hillegers *et al.* 2005; Duffy *et al.* 2009, 2014). The study by Duffy *et al.* (2014), for example, reported a cumulative incidence of 32 out of 229 high-risk individuals, and eight out of a sample of 86 control participants who developed MDD, but only three individuals from the high-risk group developed BD (and no controls), consistent with the findings reported here. The continued clinical longitudinal follow-up of these high-risk samples will make important contributions to the understanding of early phases of affective disease pathways. One other criticism could be that since there is a decrease over time in the HR MDD group, and there are no significant differences between the groups cross-sectionally at T2, this could represent regression to the mean. Ongoing scanning assessment of the individuals will provide a clearer picture of whether there is continued progressive decline in the ill group. Finally, we also highlight the practical difficulties in performing such large-scale prospective longitudinal cohort imaging studies, particularly relating to cumulative attrition over the course of the study. For this reason it was necessary for us to determine diagnostic status for a small number of individuals based on GP correspondence at T3. We acknowledge that this as a limitation in that we consequently have fewer symptom-related and subtype details for these participants.

Overall our findings suggest that development of MDD in a cohort of individuals at high familial risk of BD is related to the decreasing amygdala grey matter around the time of illness onset. Other factors such as increased levels of childhood trauma, increased neuroticism and decreased extraversion appeared to distinguish groups at baseline; however, longitudinal

change in these scores did not relate to the development of MDD, suggesting that imaging measures may capture additional information beyond clinically ascertained measures of risk and may be a useful marker of illness development.

Acknowledgements

We would like to thank all of the participants who took part in the study and the radiographers who acquired the MRI scans. This study was conducted at the Brain Research Imaging Centre (<http://www.bric.ed.ac.uk>) which is supported by SINAPSE (Scottish Imaging Network, a Platform for Scientific Excellence, <http://www.sinapse.ac.uk>). The research leading to these results has received funding from the European Community's Seventh Framework Programme (FP7/2007–2013) under grant agreement no. 602450. This paper reflects only the authors' views and the European Union is not liable for any use that may be made of the information contained therein. This work was also supported by a Wellcome Trust Strategic Award (104036/Z/14/Z).

Declaration of Interest

T.N. is supported by the Dr Mortimer and Theresa Sackler Foundation. H.C.W. is supported by a College Fellowship from the University of Edinburgh and a John, Margaret, Alfred and Stewart *Sim* (JMAS *Sim*) fellowship from the Royal College of Physicians of Edinburgh. J.E.S. is supported by a Clinical Research Training Fellowship from the Wellcome Trust. J.H. was supported by a Scottish Funding Council Senior Clinical Fellowship (SCD/10) and is currently supported by a Medical Research Council Centre grant (G0800509). A.M.M. was supported by the Health Foundation through a Clinician Scientist Fellowship (reference 2268/4295), by the Brain and Behaviour Research Foundation through a NARSAD Independent Investigator Award and by a Scottish Funding Council Senior Clinical Fellowship. The investigators also acknowledge the financial support of NHS Research Scotland, through the Scottish Mental Health Research Network (<http://www.smhrn.org.uk>) which provided assistance with subject recruitment and cognitive assessments. All imaging aspects also received financial support from the Dr Mortimer and Theresa Sackler Foundation. H.C.W., L.R., J.H., S.M.L. and A.M.M. have received financial support from Pfizer (formerly Wyeth) in relation to imaging studies of people with schizophrenia and BD. S.M.L. and A.M.M. have done consultancy work for Roche Pharmaceuticals. S.M.L. has also received honoraria for lectures, chairing meetings, and consultancy work

from Janssen in connection with brain imaging and therapeutic initiatives for psychosis. Other authors T. N., S.W.Y.C., M.P., A.M., T.S., S.K. and J.E.S. have no competing interests to declare.

References

- Alemamy S, Mas A, Goldberg X, Falcon C, Fatjo-Vilas M, Arias B, Bargalló N, Nenadic I, Gastó C, Fañanas L** (2013). Regional gray matter reductions are associated with genetic liability for anxiety and depression: an MRI twin study. *Journal of Affective Disorders* **149**, 175–181.
- Almeida JR, Versace A, Mechelli A, Hassel S, Quevedo K, Kupfer DJ, Phillips ML** (2009). Abnormal amygdala–prefrontal effective connectivity to happy faces differentiates bipolar from major depression. *Biological Psychiatry* **66**, 451–459.
- Amico F, Meisenzahl E, Koutsouleris N, Reiser M, Moller HJ, Frodl T** (2011). Structural MRI correlates for vulnerability and resilience to major depressive disorder. *Journal of Psychiatry and Neuroscience* **36**, 15–22.
- Arnone D, McIntosh AM, Ebmeier KP, Munafo MR, Anderson IM** (2012). Magnetic resonance imaging studies in unipolar depression: systematic review and meta-regression analyses. *European Neuropsychopharmacology* **22**, 1–16.
- Baare WF, Vinberg M, Knudsen GM, Paulson OB, Langkilde AR, Jernigan TL, Kessing LV** (2010). Hippocampal volume changes in healthy subjects at risk of unipolar depression. *Journal of Psychiatric Research* **44**, 655–662.
- Bechdolf A, Wood SJ, Nelson B, Velakoulis D, Yucel M, Takahashi T, Yung AR, Berk M, Wong MT, Pantelis C, McGorry PD** (2012). Amygdala and insula volumes prior to illness onset in bipolar disorder: a magnetic resonance imaging study. *Psychiatry Research* **201**, 34–39.
- Bernstein DP, Fink L** (1988). *Childhood Trauma Questionnaire: a Retrospective Self-report*. The Psychological Corporation: San Antonio, TX.
- Bitter SM, Mills NP, Adler CM, Strakowski SM, DelBello MP** (2011). Progression of amygdala volumetric abnormalities in adolescents after their first manic episode. *Journal of the American Academy of Child and Adolescent Psychiatry* **50**, 1017–1026.
- Boccardi M, Almici M, Bresciani L, Caroli A, Bonetti M, Monchieri S, Gennarelli M, Frisoni GB** (2010). Clinical and medial temporal features in a family with mood disorders. *Neuroscience Letters* **468**, 93–97.
- Bora E, Fornito A, Pantelis C, Yucel M** (2012). Gray matter abnormalities in major depressive disorder: a meta-analysis of voxel based morphometry studies. *Journal of Affective Disorders* **138**, 9–18.
- Chan SW, Goodwin GM, Harmer CJ** (2007). Highly neurotic never-depressed students have negative biases in information processing. *Psychological Medicine* **37**, 1281–1291.
- Chen MC, Hamilton JP, Gotlib IH** (2010). Decreased hippocampal volume in healthy girls at risk of depression. *Archives of General Psychiatry* **67**, 270–276.

- Desikan RS, Ségonne F, Fischl B, Quinn BT, Dickerson BC, Blacker D, Buckner RL, Dale AM, Maguire RP, Hyman BT, Albert MS, Killiany RJ (2006). An automated labeling system for subdividing the human cerebral cortex on MRI scans into gyral based regions of interest. *NeuroImage* **31**, 968–980.
- Douaud G, Smith S, Jenkinson M, Behrens T, Johansen-Berg H, Vickers J, James S, Voets N, Watkins K, Matthews PM, James A (2007). Anatomically related grey and white matter abnormalities in adolescent-onset schizophrenia. *Brain* **130**, 2375–2386.
- Drevets WC (2003). Neuroimaging abnormalities in the amygdala in mood disorders. *Annals of the New York Academy of Sciences* **985**, 420–444.
- Drevets WC, Price JL, Furey ML (2008). Brain structural and functional abnormalities in mood disorders: implications for neurocircuitry models of depression. *Brain Structure and Function* **213**, 93–118.
- Duffy A, Alda M, Hajek T, Grof P (2009). Early course of bipolar disorder in high-risk offspring: prospective study. *British Journal of Psychiatry* **195**, 457–458.
- Duffy A, Horrocks J, Doucette S, Keown-Stoneman C, McCloskey S, Grof P (2014). The developmental trajectory of bipolar disorder. *British Journal of Psychiatry* **204**, 122–128.
- Eker C, Simsek F, Yilmazer EE, Kitis O, Cinar C, Eker OD, Coburn K, Gonul AS (2014). Brain regions associated with risk and resistance for bipolar I disorder: a voxel-based MRI study of patients with bipolar disorder and their healthy siblings. *Bipolar Disorders* **16**, 249–261.
- First MB, Spitzer RL, Gibbon M, Williams JB (2002). *Structured Clinical Interview for DSM-IV-TR Axis I Disorders, Research Version, Patient Edition with Psychotic Screen*. Biometrics Research, New York State Psychiatric Institute: New York.
- Frodl T, Meisenzahl E, Zetzsche T, Bottlender R, Born C, Groll C, Jäger M, Leinsinger G, Hahn K, Möller HJ (2002). Enlargement of the amygdala in patients with a first episode of major depression. *Biological Psychiatry* **51**, 708–714.
- Frodl T, Meisenzahl EM, Zetzsche T, Born C, Jager M, Groll C, Bottlender R, Leinsinger G, Möller HJ (2003). Larger amygdala volumes in first depressive episode as compared to recurrent major depression and healthy control subjects. *Biological Psychiatry* **53**, 338–344.
- Frodl T, Moller HJ, Meisenzahl E (2008). Neuroimaging genetics: new perspectives in research on major depression? *Acta Psychiatrica Scandinavica* **118**, 363–372.
- Good CD, Johnsrude IS, Ashburner J, Henson RN, Friston KJ, Frackowiak RS (2001). A voxel-based morphometric study of ageing in 465 normal adult human brains. *NeuroImage* **14**, 21–36.
- Hajek T, Kopecek M, Kozeny J, Gunde E, Alda M, Höschl C (2009). Amygdala volumes in mood disorders – meta-analysis of magnetic resonance volumetry studies. *Journal of Affective Disorders* **115**, 395–410.
- Hamilton JP, Siemer M, Gotlib IH (2008). Amygdala volume in major depressive disorder: a meta-analysis of magnetic resonance imaging studies. *Molecular Psychiatry* **13**, 993–1000.
- Hamilton M (1960). A rating scale for depression. *Journal of Neurology, Neurosurgery and Psychiatry* **23**, 56–62.
- Heim C, Nemeroff CB (2001). The role of childhood trauma in the neurobiology of mood and anxiety disorders: preclinical and clinical studies. *Biological Psychiatry* **49**, 1023–1039.
- Hillegers MH, Reichart CG, Wals M, Verhulst FC, Ormel J, Nolen WA (2005). Five-year prospective outcome of psychopathology in the adolescent offspring of bipolar parents. *Bipolar Disorders* **7**, 344–350.
- Hovens JG, Wiersma JE, Giltay EJ, van Oppen P, Spinhoven P, Penninx BW, Zitman FG (2010). Childhood life events and childhood trauma in adult patients with depressive, anxiety and comorbid disorders vs. controls. *Acta Psychiatrica Scandinavica* **122**, 66–74.
- Karchemskiy A, Garrett A, Howe M, Adleman N, Simeonova DI, Alegria D, Reiss A, Chang K (2011). Amygdalar, hippocampal, and thalamic volumes in youth at high risk for development of bipolar disorder. *Psychiatry Research* **194**, 319–325.
- Kay SR, Fiszbein A, Opler LA (1987). The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. *Schizophrenia Bulletin* **13**, 261–276.
- Kelley R, Chang KD, Garrett A, Alegria D, Thompson P, Howe M, Reiss AL (2013). Deformations of amygdala morphology in familial pediatric bipolar disorder. *Bipolar Disorders* **15**, 795–802.
- Kendler KS, Gatz M, Gardner CO, Pedersen NL (2006). Personality and major depression: a Swedish longitudinal, population-based twin study. *Archives of General Psychiatry* **63**, 1113–1120.
- LeDoux JE (2000). Emotion circuits in the brain. *Annual Review of Neuroscience* **23**, 155–184.
- Levesque ML, Beauregard M, Ottenhof KW, Fortier E, Tremblay RE, Brendgen M, Pérusse D, Dionne G, Robaey P, Vitaro F, Boivin M, Boij L (2011). Altered patterns of brain activity during transient sadness in children at familial risk for major depression. *Journal of Affective Disorders* **135**, 410–413.
- Liu Y, Blackwood DH, Caesar S, de Geus EJ, Farmer A, Ferreira MA, Ferrier IN, Fraser C, Gordon-Smith K, Green EK, Grozeva D, Gurling HM, Hamshere ML, Heutink P, Holmans PA, Hoogendijk WJ, Hottenga JJ, Jones L, Jones IR, Kirov G, Lin D, McGuffin P, Moskvina V, Nolen WA, Perlis RH, Posthuma D, Scolnick EM, Smit AB, Smit JH, Smoller JW, St Clair D, van Dyck R, Verhage M, Willemsen G, Young AH, Zandbelt T, Boomsma DI, Craddock N, O'Donovan MC, Owen MJ, Penninx BW, Purcell S, Sklar P, Sullivan PF; Wellcome Trust Case-Control Consortium (2011). Meta-analysis of genome-wide association data of bipolar disorder and major depressive disorder. *Molecular Psychiatry* **16**, 2–4.
- MacMillan HL, Fleming JE, Streiner DL, Lin E, Boyle MH, Jamieson E, Duku EK, Walsh CA, Wong MY, Beardslee WR (2001). Childhood abuse and lifetime psychopathology in a community sample. *American Journal of Psychiatry* **158**, 1878–1883.
- Mannie ZN, Filippini N, Williams C, Near J, Mackay CE, Cowen PJ (2014). Structural and functional imaging of the hippocampus in young people at familial risk of depression. *Psychological Medicine* **44**, 2939–2948.

- Matthews SC, Strigo IA, Simmons AN, Yang TT, Paulus MP** (2008). Decreased functional coupling of the amygdala and supragenual cingulate is related to increased depression in unmedicated individuals with current major depressive disorder. *Journal of Affective Disorders* **111**, 13–20.
- McCrae RR, John OP** (1992). An introduction to the five-factor model and its applications. *Journal of Personality* **60**, 175–215.
- McGuffin P, Farmer A, Harvey I** (1991). A polydiagnostic application of operational criteria in studies of psychotic illness. Development and reliability of the OPCRIT system. *Archives of General Psychiatry* **48**, 764–770.
- McGuffin P, Rijdsdijk F, Andrew M, Sham P, Katz R, Cardno A** (2003). The heritability of bipolar affective disorder and the genetic relationship to unipolar depression. *Archives of General Psychiatry* **60**, 497–502.
- Miskowiak KW, Glerup L, Vestbo C, Harmer CJ, Reinecke A, Macoveanu J, Siebner HR, Kessing LV, Vinberg M** (2015). Different neural and cognitive response to emotional faces in healthy monozygotic twins at risk of depression. *Psychological Medicine* **45**, 1447–1458.
- Nelson HE** (1982). *National Adult Reading Test (NART): Test Manual*. NFER-Nelson, Windsor.
- Papmeyer M, Giles S, Sussmann JE, Kieley S, Stewart T, Lawrie SM, Whalley HC, McIntosh AMM** (2015). Cortical thickness in individuals at high familial risk of mood disorders as they develop major depressive disorder. *Biological Psychiatry* **78**, 58–66.
- Peyrot WJ, Milaneschi Y, Abdellaoui A, Sullivan PF, Hottenga JJ, Boomsma DI, Penninx BW** (2014). Effect of polygenic risk scores on depression in childhood trauma. *British Journal of Psychiatry* **205**, 113–119.
- Phillips ML, Drevets WC, Rauch SL, Lane R** (2003). Neurobiology of emotion perception II: implications for major psychiatric disorders. *Biological Psychiatry* **54**, 515–528.
- Rao U, Chen LA, Bidesi AS, Shad MU, Thomas MA, Hammen CL** (2010). Hippocampal changes associated with early-life adversity and vulnerability to depression. *Biological Psychiatry* **67**, 357–364.
- Romanczuk-Seiferth N, Pohland L, Mohnke S, Garbusow M, Erk S, Erk S, Haddad L, Grimm O, Tost H, Meyer-Lindenberg A, Walter H, Wüstenberg T** (2014). Larger amygdala volume in first-degree relatives of patients with major depression. *NeuroImage Clinical* **5**, 62–68.
- Sacher J, Neumann J, Funfstuck T, Soliman A, Villringer A, Schroeter ML** (2012). Mapping the depressed brain: a meta-analysis of structural and functional alterations in major depressive disorder. *Journal of Affective Disorders* **140**, 142–148.
- Saleh K, Carballedo A, Liseicka D, Fagan AJ, Connolly G, Boyle G, Frodl T** (2012). Impact of family history and depression on amygdala volume. *Psychiatry Research* **203**, 24–30.
- Savitz J, Drevets WC** (2009). Bipolar and major depressive disorder: neuroimaging the developmental–degenerative divide. *Neuroscience and Biobehavioural Reviews* **33**, 699–771.
- Schulze TG, Akula N, Breuer R, Steele J, Nalls MA, Singleton AB, Degenhardt FA, Nöthen MM, Cichon S, Rietschel M; Bipolar Genome Study, McMahon FJ** (2014). Molecular genetic overlap in bipolar disorder, schizophrenia, and major depressive disorder. *World Journal of Biological Psychiatry* **15**, 200–208.
- Shih RA, Belmonte PL, Zandi PP** (2004). A review of the evidence from family, twin and adoption studies for a genetic contribution to adult psychiatric disorders. *International Reviews of Psychiatry* **16**, 260–283.
- Smith SM, Jenkinson M, Woolrich MW, Beckmann CF, Behrens TE, Johansen-Berg H, Bannister PR, De Luca M, Drobnjak I, Flitney DE, Niazy RK, Saunders J, Vickers J, Zhang Y, De Stefano N, Brady JM, Matthews PM** (2004). Advances in functional and structural MR image analysis and implementation as FSL. *NeuroImage* **23** (Suppl. 1), S208–S219.
- Smith SM, Nichols TE** (2009). Threshold-free cluster enhancement: addressing problems of smoothing, threshold dependence and localisation in cluster inference. *NeuroImage* **44**, 83–98.
- Sprooten E, Sussmann JE, Clugston A, Peel A, McKirdy J, Moorhead TW, Anderson S, Shand AJ, Giles S, Bastin ME, Hall J, Johnstone EC, Lawrie SM, McIntosh AM** (2011). White matter integrity in individuals at high genetic risk of bipolar disorder. *Biological Psychiatry* **70**, 350–356.
- Swartz JR, Williamson DE, Hariri AR** (2014). Developmental change in amygdala reactivity during adolescence: effects of family history of depression and stressful life events. *American Journal of Psychiatry* **172**, 276–283.
- Whalley HC, Papmeyer M, Sprooten E, Romaniuk L, Blackwood DH, Glahn DC, Hall J, Lawrie SM, Sussmann J, McIntosh AM** (2012). The influence of polygenic risk for bipolar disorder on neural activation assessed using fMRI. *Translational Psychiatry* **2**, e130.
- Whalley HC, Sussmann JE, Chakirova G, Mukerjee P, Peel A, McKirdy J, Hall J, Johnstone EC, Lawrie SM, McIntosh AM** (2011). The neural basis of familial risk and temperamental variation in individuals at high risk of bipolar disorder. *Biological Psychiatry* **70**, 343–349.
- Whalley HC, Sussmann JE, Romaniuk L, Stewart T, Kieley S, Lawrie SM, Hall J, McIntosh AM** (2015). Dysfunction of emotional brain systems in individuals at high risk of mood disorder with depression and predictive features prior to illness. *Psychological Medicine* **45**, 1207–1218.
- Whalley HC, Sussmann JE, Romaniuk L, Stewart T, Papmeyer M, Sprooten E, Hackett S, Hall J, Lawrie SM, McIntosh AM** (2013). Prediction of depression in individuals at high familial risk of mood disorders using functional magnetic resonance imaging. *PLOS ONE* **8**, e57357.
- Whittle S, Lichter R, Dennison M, Vijayakumar N, Schwartz O, Byrne ML, Simmons JG, Yücel M, Pantelis C, McGorry P, Allen NB** (2015). Structural brain development and depression onset during adolescence: a prospective longitudinal study. *American Journal of Psychiatry* **171**, 564–571.
- Young RC, Biggs JT, Ziegler VE, Meyer DA** (1978). A rating scale for mania: reliability, validity and sensitivity. *British Journal of Psychiatry* **133**, 429–435.